Program
Omeprazole
Also written as “Atazanavir/Ritonavir+Omeprazole”, “omeprazole” and “Omeprazole 20 mg”.
Its studies are mostly in Gastroesophageal Reflux · Neoplasms · Laryngopharyngeal Reflux · Heartburn · HIV Infections, led by 13 companies.
Drug pageOmeprazole: every studyMany companies study it; this page follows only the 32 they lead. All 164 studies, academic ones too, with its approvals and label.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| AstraZeneca | 90 open or running | phase 4since Mar 18, 2008 | Nov 20, 2005 | none ahead |
| Bayerits history only | 40 open or running | phase 4since Apr 4, 2012 | May 2, 2008 | none ahead |
| Dr. Reddy's Laboratoriesits history only | 40 open or running | phase 1since Jan 8, 2010 | Jan 8, 2010 | none ahead |
| Boehringer Ingelheimits history only | 30 open or running | phase 1since Sep 30, 2014 | Sep 30, 2014 | none ahead |
| GlaxoSmithKlineits history only | 20 open or running | phase 1since Mar 1, 2007 | Mar 1, 2007 | none ahead |
| Procter and Gambleits history only | 20 open or running | phase 4since Dec 15, 2008 | Dec 15, 2008 | none ahead |
| Sanofiits history only | 20 open or running | phase 3since Sep 2, 2009 | Sep 2, 2009 | none ahead |
| AbbVieits history only | 10 open or running | phase 3since Apr 29, 2008 | Apr 29, 2008 | none ahead |
| Ascension Healthits history only | 10 open or running | phase 4since Jan 25, 2013 | Jan 25, 2013 | none ahead |
| Nekkar Lab Srlits history only | 11 open or running | no phasesince Oct 14, 2019 | Oct 14, 2019 | none ahead |
| Perle Bioscienceits history only | 10 open or running | phase 3since Jan 2, 2013 | Jan 2, 2013 | none ahead |
| PT Kalbe Farma Tbkits history only | 10 open or running | no phasesince Feb 8, 2023 | Feb 8, 2023 | none ahead |
| SD Biosensorits history only | 10 open or running | phase 4since Jan 19, 2009 | Jan 19, 2009 | none ahead |
Also a collaborator on its studies: PT Pharma Metric Labs, Parexel, Medpace, Syreon, Bausch Health Companies, Ferring Pharmaceuticals and Tanabe Pharma.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of AstraZeneca only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Nov 20, 2005First studies: 3 phase 3 studiesFirst studyNCT00256737, NCT00259077, NCT00259051
- Nov 17, 2006Phase 3 study in Gastrointestinal HemorrhageNCT00402259 · 440 enrolled · China
- Mar 18, 2008Phase 4 study in Laryngopharyngeal RefluxNCT00641264 · 90 enrolled
- Jul 8, 2010Phase 1 study in Pharmacodynamics StudyNCT01159145 · 42 enrolled · Japan
- Aug 5, 2013Phase 1 study in Bioequivalence, AUC, Cmax, PharmacokineticsNCT01921920 · 54 enrolled · United States
- Jun 8, 2021Phase 1 study in Advanced Solid TumoursNCT04959266 · 5 enrolled · United States, Spain
- Apr 1, 2022Phase 1 study in HealthyNCT05319912 · 18 enrolled · United States
TargetBeta
“Potassium-transporting ATPase inhibitor; Potassium-transporting ATPase inhibitor”ChEMBL 37, by rule
Other programs on the same two targets
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| Esomeprazolerule | AstraZeneca | phase 4 | 129 |
| Rabeprazolerule | Eisai | phase 4 | 66 |
| tegoprazanrule | HK inno.N | phase 4 | 48 |
| vonoprazanrule | Takeda | phase 4 | 48 |
| fexuprazanrule | Daewoong Pharmaceutical | phase 4 | 29 |
Studies
All 9 AstraZeneca leads, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT05319912Healthy · United States | 1 | Completed | May 29, 2014 | 18 |
| NCT04959266Advanced Solid Tumours · United States, Spain | 1 | Terminated | Jun 1, 2022 | 5 |
| NCT01921920Bioequivalence, AUC, Cmax, Pharmacokinetics · United States | 1 | Completed | Nov 2013 | 54 |
| NCT01159145Pharmacodynamics Study · Japan | 1 | Completed | Sep 2010 | 42 |
| NCT00641264Laryngopharyngeal Reflux | 4 | Completed | Jun 2003 | 90 |
| NCT00402259Gastrointestinal Hemorrhage · China | 3 | Completed | 440 | |
| NCT00259077Non-Erosive Reflux Disease · Japan | 3 | Completed | Jul 2004 | 270 |
| NCT00259051Non-Erosive Reflux Disease · Japan | 3 | Completed | Aug 2004 | 40 |
| NCT00256737Gastroesophageal Reflux · Denmark, Finland, Norway and more | 3 | Completed | Oct 2005 | 219 |
How it is read
Names in the registry
- “Omeprazole”, 30 entries
- “Atazanavir/Ritonavir+Omeprazole”, 4 entries
- “omeprazole”, 3 entries
- “Omeprazole 20 mg”, 2 entries
- “Omeprazole/sodium bicarbonate”, 2 entries
Conditions, from the studies’ own filings
- Gastroesophageal Reflux, 3 studies
- Neoplasms, 2 studies
- Laryngopharyngeal Reflux, 2 studies
- Heartburn, 2 studies
- HIV Infections, 2 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.